Related Experiment Video
Updated: Sep 13, 2025
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
HHV-6 and EBV reactivation in relapsing remitting multiple sclerosis: Disability, progression, and inflammation links
Abbas F Almulla1,2,3,4, Aristo Vojdani5,6, Yingqian Zhang1,2
1Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
Abstract:
Reactivation of human herpesvirus 6 (HHV-6) and Epstein-Barr virus (EBV) is observed in multiple sclerosis (MS). This study investigates immunoglobulins (Ig)G, IgM, and IgA responses to EBV nuclear antigen EBNA (peptide 386-405), HHV-6 (peptide 300-322) and EBV (peptide 243-268) deoxyuridine-triphosphatase (dUTPase), and different immune profiles in 58 patients with relapsing remitting MS (RRMS) compared to 60 healthy controls. IgA/IgG/IgM were measured utilizing enzyme-linked immunosorbent assays, and cytokines, chemokines, and growth factors utilizing multiplex immunoassays. RRMS patients showed significantly increased IgG, IgA, and IgM responses to all three viral antigens. IgG and IgM to HHV-6 dUTPase discriminated RRMS patients from controls with 91.5% accuracy. Neural network analysis combining EBV-dUTPase antibodies and immune profiles yielded 97.1% predictive accuracy. IgG/IgM responses to dUTPases correlated with Expanded Disability Status Scale/MS Severity Score and aberrations in M1 macrophage, Th17 profiles, and overall immune activation. HHV-6 and EBV reactivation contribute to RRMS through cytokine-driven immune activation.
